Hong Kong · Delayed Price · Currency is HKD VISEN Pharmaceuticals Statistics
Total Valuation
HKG:2561 has a market cap or net worth of HKD 2.68 billion. The enterprise value is 2.18 billion.
| Market Cap | 2.68B |
| Enterprise Value | 2.18B |
Important Dates
The next estimated earnings date is Thursday, April 30, 2026.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:2561 has 109.04 million shares outstanding. The number of shares has increased by 10.71% in one year.
| Current Share Class | 109.04M |
| Shares Outstanding | 109.04M |
| Shares Change (YoY) | +10.71% |
| Shares Change (QoQ) | +7.23% |
| Owned by Insiders (%) | 4.98% |
| Owned by Institutions (%) | n/a |
| Float | 25.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17,737.64 |
| PB Ratio | 3.17 |
| P/TBV Ratio | 3.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.72 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.47, with a Debt / Equity ratio of 0.23.
| Current Ratio | 4.47 |
| Quick Ratio | 3.00 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -218.42 |
Financial Efficiency
Return on equity (ROE) is -50.52% and return on invested capital (ROIC) is -25.35%.
| Return on Equity (ROE) | -50.52% |
| Return on Assets (ROA) | -23.58% |
| Return on Invested Capital (ROIC) | -25.35% |
| Return on Capital Employed (ROCE) | -31.29% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 1,846 |
| Profits Per Employee | -3.44M |
| Employee Count | 82 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.08% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -49.08% |
| 50-Day Moving Average | 29.32 |
| 200-Day Moving Average | 37.58 |
| Relative Strength Index (RSI) | 34.48 |
| Average Volume (20 Days) | 16,195 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:2561 had revenue of HKD 151,342 and -282.01 million in losses. Loss per share was -2.72.
| Revenue | 151,342 |
| Gross Profit | -11,128 |
| Operating Income | -266.88M |
| Pretax Income | -282.01M |
| Net Income | -282.01M |
| EBITDA | -266.08M |
| EBIT | -266.88M |
| Loss Per Share | -2.72 |
Balance Sheet
The company has 704.01 million in cash and 196.95 million in debt, with a net cash position of 507.06 million or 4.65 per share.
| Cash & Cash Equivalents | 704.01M |
| Total Debt | 196.95M |
| Net Cash | 507.06M |
| Net Cash Per Share | 4.65 |
| Equity (Book Value) | 848.02M |
| Book Value Per Share | 7.78 |
| Working Capital | 813.57M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 820,667 |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | -7.35% |
| Operating Margin | -176,339.20% |
| Pretax Margin | -186,339.94% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HKG:2561 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.71% |
| Shareholder Yield | -10.71% |
| Earnings Yield | -10.51% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |